Pramlintide brand name SymlinPen, is an injectable medication used as an adjunct to mealtime insulin for managing blood sugar levels in adults with type 1 or type 2 diabetes who have not achieved optimal glucose control with insulin alone.
It is an analog of the naturally occurring pancreatic hormone amylin.
Pramlintide helps regulate blood glucose through three primary mechanisms:
Slows gastric emptying, which delays the rate at which food-derived glucose enters the bloodstream after a meal.
Suppresses post-meal glucagon secretion from the liver, preventing excess glucose production.
Increases satiety which can lead to reduced food intake and modest weight loss.
It is administered as a subcutaneous injection immediately before major meals (those with at least 250 calories or 30 grams of carbohydrates).
Never mixed with insulin in the same syringe or injection pen.
When initiating pramlintide, mealtime insulin doses must be reduced by 50% to minimize the risk of severe hypoglycemia.
The most common side effects are mild to moderate and tend to decrease over time: Nausea and vomiting Loss of appetite Headache Fatigue
The most significant risk is severe hypoglycemia which can occur within three hours of injection, especially in patients with type 1 diabetes.
Patients should always have a source of fast-acting sugar available and monitor blood glucose levels frequently.
Pramlintide should not be used in patients with gastroparesis or those with hypoglycemia unawareness.
Oral medications that require rapid absorption should be taken at least 1 hour before or 2 hours after a pramlintide injection due to its effect on gastric emptying.
Used as an adjunctive treatment with mealtime insulin for adults with type 1 or type 2 diabetes who have failed to achieve adequate blood sugar control with insulin alone.
It is not a substitute for insulin and must be used as a separate injection.
The primary risk is severe, insulin-induced hypoglycemia, especially during the first 3 hours after injection.
To mitigate this risk, mealtime insulin doses must be reduced by up to 50% when starting pramlintide.
Common Side Effects: Nausea, vomiting, and loss of appetite are the most common side effects, typically mild to moderate and decreasing over time as the body adjusts to the medication.